MORRIS PLAINS, N.J., May 13, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract. These presentations will occur at the 2010 annual Congress of the European League Against Rheumatism (EULAR), June 16 – 19, 2010, in Rome, Italy. In the second half of 2010, UCB will initiate two Phase III studies of epratuzumab for the treatment of patients with moderate and severe lupus.
